OraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab® Production Scales Up Total 2021 revenue of $233.7 million, up 36% year-over year . | February 23, 2022
Dive into Petaluma's Della Fattoria sonomacountygazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sonomacountygazette.com Daily Mail and Mail on Sunday newspapers.
With governments ramping up COVID-19 testing in priority settings such as airports, schools and essential workplaces as more infectious variants of the virus emerge in Canada, a Kanata company says its newly approved device used in saliva-based tests could pave the way for a faster reopening of the economy.
DNA Genotek announced this week that Health Canada has given the green light to its saliva collection kit for emergency use. Diagnostic labs and public health authorities now have access to the device for COVID-19 testing.
Company officials say the system could make it easier to detect coronavirus infections, especially in children and others unable to tolerate a nasopharyngeal swab.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
OraSure Subsidiary DNA Genotek’s OMNIgene®·ORAL Included in EUA Granted to Ambry Genetics for .
OraSure Technologies, Inc.January 29, 2021 GMT
BETHLEHEM, Pa., Jan. 29, 2021 (GLOBE NEWSWIRE) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its OMNIgene®·ORAL (OM-505) saliva collection kit, a product of subsidiary DNA Genotek, was included in the Emergency Use Authorization (EUA) granted to Ambry Genetics for use in its Ambry COVID-19 RT-PCR saliva test. OMNIgene®·ORAL will be utilized for non-invasive and self-administered collection and stabilization of saliva for the detection and identification SARS CoV-2 RNA. This is the eighth EUA to include a collection device from the Company’s DNA Genotek subsidiary.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
OraSure’s OMNIgene®·ORAL Saliva Collection Kit Selected by Chronomics for Use in UK Government .
OraSure Technologies, Inc.January 26, 2021 GMT
BETHLEHEM, Pa., Jan. 26, 2021 (GLOBE NEWSWIRE) OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Chronomics Limited has selected the OMNIgene®·ORAL (OME-505) saliva collection device as a component of its SARS CoV-2 PCR test. Chronomics Limited will supply its test for the United Kingdom’s “Test to Release for International Travel” program. The OMNIgene®·ORAL device is a product of OraSure’s DNA Genotek subsidiary.